11 Jun 2019 – The trial with panel C has started, aiming at evaluating the safety and tolerability of PBTZ169 at a dose of 600 mg, once a day for 14 days, in healthy volunteers.
27 May 2019 – The Trial Safety Board assessed the safety and tolerability parameters for panels A and B, and authorized dose escalation as no salient adverse events were observed with PBTZ169 300 mg administered b.i.d. for 2 weeks. The trial will continue with panel C (600 mg q.d.) scheduled for June 2019.
11 Mar 2019 – The phase Ib trial (multiple ascending doses) officially started, dose escalation will be performed through 4 panels A, B, C and D.
